Mission Bio has launched the Tapestri Single-cell Multiple Myeloma Multiomics Solution, designed to advance research and therapeutic development for multiple myeloma by offering comprehensive insights into the disease at the single-cell level.
The new solution offers multiple flexible assays that provide detailed insights into the genetic and cellular landscape of myeloid progression, resistant therapy, and disease relapse. This includes the Multiple Myeloma DNA Panel for gene coverage, a Genome-wide CNV Panel for evaluating clonal heterogeneity, a Multiple Myeloma Antibody Cocktail for cell-type classification and target identification, and an automated data analysis and reporting system.
The company claims that the solution can optimize immunotherapy applications and discover the molecular pathogenesis of multiple myeloma by providing early indicators of therapeutic effectiveness.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.